Skip to content

Metabolic and Immunological Phenotyping in Patients With Cancer

Metabolic and Immunological Phenotyping in Patients With Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04285242
Acronym
MIPPaC
Enrollment
80
Registered
2020-02-26
Start date
2021-12-07
Completion date
2024-06-01
Last updated
2024-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Non-Hematologic Malignancy

Keywords

Cancer, Non-haematological

Brief summary

An observational study to investigate cachexia in participants with non-haematological cancer.

Detailed description

A single-centre, non-randomised, observational study. This study will investigate the systemic metabolic and immunological changes that occur in cachexia. The aim is to better understand the mechanism(s) underlying weight loss in people with non-haematological cancer. This will help to facilitate future research to generate treatments to reverse weight loss and improve outcomes.

Interventions

OTHERObservational assessments

Clinical assessments

Sponsors

CCTU- Cancer Theme
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Have given written informed consent to participate * Be aged 18 years or over at the time of signing the informed consent form * Have a histological or cytological diagnosis of a non-haematological cancer * Are willing and able to comply with study procedures and visits

Exclusion criteria

* Active infection, as determined by the investigator based on clinical symptoms and / or fever and / or requirement for antibiotics * Current treatment with chemotherapy, oral steroids or other immunosuppressive drugs (within 7 days of baseline investigations or during the study phase) * Significant acute, chronic or psychiatric condition or laboratory abnormality which in the judgment of the investigator would place the patient at undue risk or interfere with the study. * Intolerance to dairy products * Women, who are pregnant, plan to become pregnant or are lactating

Design outcomes

Primary

MeasureTime frameDescription
Serum cortisol levelChange from baseline serum cortisol level at Day 2Blood serum cortisol levels in weight losing and weight stable patients at baseline and Day 2

Countries

United Kingdom

Contacts

Primary ContactEarly Phase Team Cambridge Cancer Trials Unit - Cancer Theme
cuh.cctuep@nhs.net01223216083
Backup ContactCambridge Cancer Trials Centre, Coordination Team
cuh.cctu-ct@nhs.net01223216083

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026